Biocryst (NASDAQ: BCRX) director executes option exercise and share disposition

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC director Jon P. Stonehouse reported several equity transactions. On March 2, 2026, he exercised an employee stock option for 305,995 shares of common stock at an exercise price of $3.22 per share, converting the derivative into common stock.

That same day, he reported a disposition of 305,995 common shares at a weighted average price of $8.64 per share; a footnote states these shares were sold in multiple transactions between $8.54 and $8.81 under a pre-established Rule 10b5-1 trading plan, and the transaction occurred automatically. After this, his direct common stock holdings were 1,323,850 shares.

On February 27, 2026, he also acquired 421 common shares at $8.75 per share, issued in lieu of 50% of a prorated quarterly cash board retainer of $7,375. In addition, there are 40,000 common shares held indirectly in each of two irrevocable trusts, where his wife serves as co-trustee.

Insider Trade Summary

305,995 shares exercised/converted

Mixed 6 txns

Insider Stonehouse Jon P

Role Director

Type	Security	Shares	Price	Value
Exercise	Emp. Stock Option (Right to Buy)	305,995	$0.00	--
Exercise	Common Stock	305,995	$3.22	$985K
Disposition	Common Stock	305,995	$8.64	$2.64M
Grant/Award	Common Stock	421	$8.75	$4K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Emp. Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 1,629,845 shares (Direct); Common Stock — 40,000 shares (Indirect, By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust)

Footnotes (1)

1. Shares of Common Stock issued to the reporting person in lieu of 50% of the prorated quarterly cash Board Member retainer of $7,375. This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stonehouse Jon P

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		421(1)	A	$8.75	1,323,850	D
Common Stock	03/02/2026		M		305,995(2)	A	$3.22	1,629,845	D
Common Stock	03/02/2026		D		305,995(2)	D	$8.64(3)	1,323,850	D
Common Stock								40,000	I	By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
Common Stock								40,000	I	By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Emp. Stock Option (Right to Buy)	$3.22	03/02/2026		M			305,995(2)	05/23/2017	05/23/2026	Common Stock	305,995	$0	0	D

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 50% of the prorated quarterly cash Board Member retainer of $7,375.

2. This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

3. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

	/s/ Alane P. Barnes, by power of attorney	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BCRX director Jon Stonehouse report in this Form 4 filing?

Jon P. Stonehouse reported exercising options for 305,995 Biocryst Pharmaceuticals shares, disposing of the same number of common shares, receiving 421 share-equivalent board compensation shares, and reporting indirect holdings in two irrevocable trusts, all as part of his updated ownership disclosure.

How many BIOCRYST PHARMACEUTICALS (BCRX) shares did Jon Stonehouse exercise and dispose of?

He exercised options into 305,995 Biocryst Pharmaceuticals common shares at a $3.22 exercise price, then reported a disposition of 305,995 common shares at a weighted average price of $8.64 per share, as detailed in the Form 4 and related footnotes.

Was Jon Stonehouse’s BCRX share disposition part of a Rule 10b5-1 trading plan?

Yes. A footnote explains the transaction occurred automatically under a Rule 10b5-1 trading plan adopted in November 2022 and modified in May 2024, indicating the sales were pre-arranged rather than discretionary market-timing decisions by Stonehouse.

What is Jon Stonehouse’s direct ownership in BCRX after these transactions?

After exercising options, disposing of shares, and receiving a stock award, Jon Stonehouse directly holds 1,323,850 shares of Biocryst Pharmaceuticals common stock, according to the post-transaction ownership figures reported in the Form 4 filing.

How was BCRX board compensation reflected in Jon Stonehouse’s Form 4?

He received 421 Biocryst Pharmaceuticals common shares at $8.75 per share, issued instead of 50% of a prorated quarterly cash board retainer of $7,375, illustrating partial equity-based director compensation rather than all-cash payment.

What indirect BCRX holdings related to Jon Stonehouse are disclosed?

The Form 4 lists 40,000 Biocryst Pharmaceuticals common shares held indirectly in each of two irrevocable trusts, one for Caroline Stonehouse and one for Samuel Stonehouse, where his wife serves as co-trustee, reflecting indirect beneficial ownership.